8-K: Quanterix Announces Preliminary Q4 and Full Year 2024 Financial Results and Provides Update on Akoya Biosciences Acquisition

Quanterix reports preliminary unaudited Q4 2024 revenue of approximately $34.9 million and full year 2024 revenue of approximately $137.2 million, representing 12% year-over-year growth for the full year, while also highlighting the pending acquisition of Akoya Biosciences.

Summary

• Quanterix Corporation announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024.
• Q4 2024 revenue is approximately $34.9 million, representing an 11% year-over-year increase.
• Full year 2024 revenue is approximately $137.2 million, reflecting a 12% year-over-year growth.
• The company used approximately $4.4 million of cash in Q4 2024 and $32 million for the full year.
• Quanterix ended the year with approximately $292 million in cash, cash equivalents, marketable securities, and restricted cash.
• The company is in the process of acquiring Akoya Biosciences and anticipates creating significant value through new growth and robust execution.
• Quanterix's President and CEO, Masoud Toloue, will present at the J.P. Morgan Healthcare Conference on January 15, 2025.
• The company will release its full Q4 and full year 2024 financial results on March 17, 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the double-digit revenue growth and the strategic acquisition of Akoya Biosciences, but tempered by the decline in instruments revenue and cash usage.

Positives

• Quanterix achieved double-digit revenue growth for the seventh consecutive quarter.
• Full year revenue increased by 12% year-over-year.
• The company has a strong cash position of approximately $292 million.
• The acquisition of Akoya Biosciences is expected to drive new growth and value.
• Accelerator and Other revenue streams showed significant growth.

Negatives

• Instruments revenue declined by 6% in Q4 2024 and 33% for the full year.
• Consumables revenue remained flat year-over-year in Q4 2024.
• The company used $32 million of cash in the twelve months ended December 31, 2024.

Risks

• The preliminary financial information is unaudited and subject to change.
• The completion of the Akoya Biosciences acquisition is subject to regulatory and stockholder approvals.
• The integration of Akoya Biosciences may present challenges and may not result in the anticipated synergies.
• The company faces risks related to the capital spending environment and competitive factors.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Quanterix expects to continue building on its performance in 2025 and anticipates creating tremendous value through the acquisition of Akoya Biosciences by driving new growth and applying robust execution to the combined company.

Management Comments

• 'I am pleased with our teams execution as we delivered our seventh consecutive quarter of double-digit revenue growth,' said Masoud Toloue, PhD, President and Chief Executive Officer of Quanterix.
• 'Despite a difficult capital spending environment, Quanterix has shown operational resiliency, and we expect to continue to build on this performance, as we enter 2025 from a position of strength.'
• 'I am also excited about our recently announced acquisition of Akoya Biosciences. We believe we can create tremendous value by driving new growth and applying the same robust execution to the combined company.'

Industry Context

Quanterix operates in the life sciences and diagnostics industry, where companies are focused on developing and commercializing advanced technologies for biomarker detection and analysis; the acquisition of Akoya Biosciences reflects a trend towards consolidation and expansion of capabilities within the industry to offer more comprehensive solutions.

Comparison to Industry Standards

• Quanterix's revenue growth of 12% for the full year 2024 is a solid performance in the diagnostics and life sciences tools industry.
• Companies like Bio-Techne and Abcam, which also provide tools and services for life sciences research, have seen varying growth rates depending on their specific market segments and product portfolios.
• The acquisition of Akoya Biosciences is a strategic move similar to other consolidations in the industry, such as Danaher's acquisition of Cytiva, aimed at expanding product offerings and market reach.
• Quanterix's cash position of $292 million provides a strong foundation for future investments and acquisitions, comparable to other well-capitalized companies in the sector.

Stakeholder Impact

• Shareholders can expect potential value creation through the acquisition of Akoya Biosciences.
• Employees may experience changes related to the integration of the two companies.
• Customers will benefit from a broader range of products and services.
• The company's financial performance and strategic initiatives may impact suppliers and creditors.

Next Steps

• Completion of financial closing procedures, internal reviews, and annual audit procedures.
• Finalization of the acquisition of Akoya Biosciences, subject to regulatory and stockholder approvals.
• Presentation at the J.P. Morgan Healthcare Conference on January 15, 2025.
• Release of full Q4 and full year 2024 financial results on March 17, 2025.

Key Dates